Newer antiviral agents and therapeutic approaches for chronic hepatitis b
- Cite this article as:
- Yao, F.Y. Curr hepatitis rep (2006) 5: 14. doi:10.1007/s11901-006-0018-8
A new era in the treatment of chronic hepatitis B began approximately a decade ago. Three oral nucleoside or nucleotide analogues—lamivudine, adefovir dipivoxil, and entecavir—are now approved in the United States for the treatment of chronic hepatitis B. Other new oral agents, including telbivudine, clevudine, and emtricitabine, are in various stages of clinical investigation. This article reviews the efficacy and resistance data of these oral antiviral agents, and the preliminary results of combination therapy for chronic hepatitis B.